Hematology Clinic
Boston Hemophilia Center
Hematology Administration
Clinical Research
Clinical Research Studies
Research Team
Research Faculty
Sickle Cell Anemia
The Hematology Clinic
The majority of our patients are seen in the Adult Hematology Clinic at Dana Farber Cancer Institute. This facility provides examination rooms, consultation rooms, and access to a thirty-chair infusion suite. The infusion suite is used to administer blood products and for the treatment of sickle cell patients with painful crisis. The clinic offers consultative opinions and continuing care in the following areas:
- Anticoagulation Problems from:
- Warfarin
- Low Molecular Weight Heparin
- Anti-platelet Agents
- Coagulation Disorders
- Hemophilia
- vonWillebrand's Disease
- Iron Metabolism Disorders
- Hemochromatosis
- Porphyria
- Myeloproliferative Disorders
- Polycythemia Vera
- Thrombocythemia
- Plasma Cells and Antibody Production Disorders
- Benign Monoclonal Gammopathy
- Cryoglobulinemia
- Amyloidosis
- Platelet Disorders
- Thrombocytopenia
- Thrombocytosis
- Red Blood Cell Disorders
- Sickle Cell Anemia
- Aplastic Anemia
- Myelodysplasia
- Other Anemias
- Thrombotic Disorders
- Factor V Leiden
- Paroxysmal Nocturnal Hemoglobinuria
- White Blood Cell Disorders
The Treatment Team
The Hematology Program at Dana-Farber/Brigham and Women's Cancer Center is staffed with board-certified hematologists who are supported in their work by hematopathologists, specialists in transfusion medicine, specialists in nuclear medicine, as well as extensive laboratories providing up to date hematology, coagulation and clinical immunology evaluations.
Clinical Faculty
| Nancy Berliner, M.D., Division Chief |
White Cell Disorders
Myelodysplasia
Myeloproliferative Disease
Hypercoaguable States
Thrombocytopenia
|
| H. Franklin Bunn, M.D. |
Red Blood Cell Disorders
Iron Metabolism Disorders
Sickle Cell Anemia |
| W. Hallowell Churchill, M.D. |
Hemolytic Anemias
MGUS
Myloproliferative Diseases
Iron Metabolism
Thrombosis
Hemoglobinopathies
|
| Jean Connors, M.D. |
Hematology Disorders in Pregnancy
General Hematology |
| Robert Handin, M.D. |
Coagulation Disorders
|
| Judith Lin, M.D. |
Bleeding Disorders
Hemophilias
von Willebrand's Disease
Thrombotic Disorders
Antiphospholipid Antibody Syndrome
Hemochromatosis
Myeloproliferative Disorders
Platelet Disorders
White Blood Cell Disorders
Anemias
|
| Ronald McCaffrey, M.D. |
General Hematology
|
| Maureen Okam, M.D. |
Red Cell Disorders
Myeloproliferative Disorders |
Nursing Staff:
Elyse Mandell, MSN, RNCS
Paula Temoczko, NP
Carole K. Tremonti, RN
Hematology Clinic Info:
- Appointments:
New Patients: (617) 732-6089
Return Appointments: (617) 732-5048
Cancel/Reschedule: (617) 632-6678 or (617) 632-4131
- Clinic Location:
Gosman Clinics
Dana Farber Cancer Institute
44 Binney Street
Boston, MA 02115
[top]
Boston Hemophilia Center
A combined program of the Brigham and Women's Hospital, Children's Hospital Boston and Dana Farber Cancer Institute, the Boston Hemophilia Center cares for more than 400 adults and children with congenital bleeding disorders. Patients are offered comprehensive outpatient and hospital services by a multidisciplinary staff consisting of physicians, nurse specialists, physical therapists, and social workers. Our care model emphasizes the integration of orthopedic and infectious disease care along with active patient and family participation. Children and adolescents with hemophilia and related disorders are seen at Children's Hospital Boston. Adult patients are seen at the Brigham and Women's Hospital and the Dana Farber Cancer Institute.
Hemophilia Clinics:
- Adult Clinic
First and third Tuesday afternoons of each month
Brigham & Women's Hospital
75 Francis Street
PBB 4th Floor
Boston, MA 02115
Appointments: (617) 732-5844
Dana Farber Cancer Institute by appointment
Appointments: (617) 732-5844
- Pediatric Clinic
Monday afternoons, Wednesday mornings, Friday afternoons
Children's Hospital Boston
300 Longwood Avenue
Fegan 6
Boston, MA 02115
Appointments: (617) 355-6101
Boston Hemophilia Center Staff Directory:
Ellis J. Neufeld, MD, PhD
Director
Phone: (617) 355-6101
Fax: (617) 730-0934
CH Page Operator: (617) 355-6363
Judith Lin, MD
Associate Director
Phone: (617) 732-5844
Fax: (617) 732-5706
BWH Page Operator: (617) 732-6660
Rhonda Fritz, MSN, PNP
Nurse Practitioner
Phone: (617) 355-6101
Fax: (617) 730-0641
CH Page Operator: (617) 355-6363
Elyse Mandell, MSN, RNCS
Nurse Practitioner
Phone: (617) 732-5844
Fax: (617) 732-5706
BWH Page Operator: (617) 732-6660
Laura Gray, LICSW
Social Worker
Phone: (617) 355-6101
Fax: (617) 730-0641
CH Page Operator: (617) 355-6363
Kathleen Richards, PT, PCS
Physical Therapist
Phone: (617) 355-7212
Fax: (617) 730-0151
CH Page Operator: (617) 355-6363
Clifford Haas
Factor Program Administrator
Phone: (617) 732-5844
Fax: (617) 732-5706
Katherine Cahill
Administrative Assistant
Phone: (617) 525-8337
Fax: (617) 732-5706
[top]
Hematology Administration
Hematology Division Director
Nancy Berliner, MD
Jane W. Carey
Division Administrator
Phone: (617) 732-5840
Fax: (617) 732-5706
Jackie Gifford
Administrative Coordinator
Phone: (617) 732-5840
Fax: (617) 732-5706
Jan Boyden
Administrative Coordinator
Phone: (617) 355-9066
Fax: (617) 355-9016
Fern Ganley
Grants Manager
Phone: (617) 355-9002
Fax: (617) 355-9061
Ella Green
Financial Coordinator
Phone: (617) 355-9065
Fax: (617) 355-9061
Katherine Cahill
Administrative Secretary
Phone: (617) 525-8337
Fax: (617) 732-5706
Annie Gauger
New Patient Coordinator
Phone: (617) 732-6089
Fax: (617) 732-5706
Claudia Flores
Medical Secretary
Phone:(617)732-5048
Fax: (617) 732-5706
[top]
Clinical Research
Clinical Research Staff:
Carole K. Tremonti , RN
Clinical Research Nurse
617-462-7984
Ashley Palmer
Clinical Research Coordinator
617-732-8537
Mary Grady
Clinical Research Coordinator
617-732-8537
Clinical Studies
Myelodysplastic Syndrome
Do you have Myelodysplastic Syndrome (MDS) or Aplastic Anemia (AA)? If so, you may be eligible to participate in a research study. We are looking to determine the prevalence of a gene found in the blood called Paroxysmal Nocturnal Hemoglobinuria (PNH). Participation in the study involves giving one blood sample and a brief medical history. Please contact Carole K. Tremonti, R.N. at (617) 462-7984 for further information.
Calling Out to Sickle Cell Patients:
Doctors in Boston need your help to explore an experimental treatment for pain associated with sickle cell disease. A research study being conducted at Brigham and Women’s Hospital is investigating whether an inhaled treatment can reduce the length of time you experience a painful crisis. This study is being conducted through a cooperative agreement between the National Institutes of Health and the pharmaceutical company INO Therapeutics, which makes the drug being tested.
If you choose to participate in this study, you will receive careful treatment and monitoring by doctors and individualized care for your pain. To be eligible to enroll, you must be at least 10 years old and have sickle cell disease with periodic painful crises.
Don’t wait until you are in a crisis situation. To find out more about the study and to learn how to enroll, please call Carole Tremonti, RN at (617) 278-0377.
Research Team
Members of the research team have been recognized for outstanding research by the Howard Hughes Institute, the American Cancer Society, The Center for Blood Research, and the American Society of Hematology. In 2004, the research team consolidated and relocated its laboratory research program to a new building on Longwood Ave. More than thirty clinical and research staff have faculty appointments at the Harvard Medical School. The Hematology Division's research activities include both basic and clinical research. A summary of our researchers' current investigations follows:
Research Faculty
Nancy Berliner, M.D., studies the transcriptional regulation of neutrophil differentiation and function. She has elucidated the regulatory pathways governing late neutrophil-specific gene expression and their disruption in leukemia, myelodysplasia, and specific granule deficiency.
H. Franklin Bunn, M.D., is recognized for his past research into hemoglobin structure and function. He participated in the identification of hemoglobin glycosylation, a phenomenon that has been translated into standard monitoring of diabetic patients worldwide. Recently, his work concerns identification of the mechanisms by which changes in oxygen tension regulate erythropoietin production.
James Cunningham, M.D., Ph.D., has discovered cell surface receptors that mediate the entry of viruses into cells. He and his colleagues have solved the atomic structures of some of these receptors; this information is of fundamental importance for future technologies designed to combat cytopathic and oncogenic viruses in animals and humans.
Gary Gilbert, M.D., based at the West Roxbury VA Hospital, has performed investigations on the role of phospholipids in the activation of blood coagulation factors.
Gary Gilliland, M.D., Ph.D., has discovered genetic mutations associated with leukemogenesis in humans and has extended this knowledge to understand how these and other mutations derange signal transduction pathways eventuating in malignant transformation, proliferation, and invasion of myeloid and lymphoid cells.
David Golan, M.D., Ph.D., based primarily in the Department of Biochemistry and Molecular Pharmacology at Harvard Medical School, has utilized biophysical imaging technology to study the mobility of surface components on blood cell membranes. He has had a major role in the teaching of pharmacology to students at Harvard Medical School.
Robert Handin, M.D., is an authority on platelet-to-vessel wall adhesion, specifically focusing on the major platelet surface glycoprotein Ib complex that interacts with von Willebrand factor. He is using this information to design potential new antithrombotic agents. Recently, he has begun to examine the genetics of platelet production using a zebrafish system.
Barry Paw, M.D. The focus of Barry Paw's laboratory research is studying genes important for red cell and platelet development using the zebrafish as a genetic model organism. Using the advantages of zebrafish genetics and developmental biology, the Paw lab has undertaken forward genetic (mutagenesis) screens to isolate zebrafish mutants with defects in hematopoiesis. The genes disrupted in these mutants are then identified by a combination of positional and candidate cloning strategies as a way to gain insight into the genetic basis of vertebrate hematopoiesis. The biological functions of the identified genes are studied in zebrafish embryos and complementary model systems, such as mouse (cultured cells and transgenic mice) and yeast.
Send Feedback to: 
